You just read:

DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver Meeting® 2019

News provided by

DURECT Corporation

Oct 21, 2019, 10:12 ET